-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 8, Kaifeng Pharmaceutical announced that the China Phase II clinical trial of freitan (tincture) for the treatment of androgenetic alopecia has reached the primary endpoint
The Phase II clinical trial conducted in China is a multi-center, randomized, double-blind, placebo-controlled clinical study involving 120 subjects in order to evaluate the effectiveness of freitan in the treatment of androgenetic alopecia in adult men.
The results showed that Freitaen is safe for the treatment of androgenetic alopecia.
Note: The original text has been deleted